2050年に人類は120歳まで生きられるか？長寿革命の全貌

In 1950, the average human life expectancy was 47 years. Today it is 73. By mid-century, a growing number of scientists, investors, and policymakers believe that figure could approach 100 — and that the first humans to reach 120 in good health may already be alive.

This is not science fiction. It is the convergence of breakthroughs in cellular biology, artificial intelligence, and regenerative medicine with an unprecedented flow of capital into what is now called the longevity economy. And no country on earth is better positioned to lead — and more urgently compelled to act — than Japan.

The Science: Why the Biology of Aging Is No Longer Fixed

For most of medical history, aging was treated as an immutable backdrop — the terrain on which diseases occurred, but not itself a condition to be addressed. That paradigm is collapsing.

Senolytics — drugs that selectively clear senescent “zombie” cells that accumulate with age and drive chronic inflammation — have moved from laboratory curiosity to clinical reality. Unity Biotechnology is in Phase 2 trials targeting age-related eye diseases, while a growing pipeline of senolytic compounds is being tested against conditions from osteoarthritis to pulmonary fibrosis. The premise is radical in its simplicity: rather than treating the diseases of aging one by one, eliminate the cellular dysfunction that causes them all.

Gene therapy and epigenetic reprogramming represent an even more fundamental intervention. Altos Labs, founded in 2022 with $3 billion in backing from investors including Yuri Milner and Jeff Bezos, is pursuing cellular rejuvenation — using Yamanaka factors to reprogram aged cells back to a younger state without turning them cancerous. Rejuvenate Bio is applying similar techniques in animal models, demonstrating measurable reversal of age-related biomarkers. The science is early, but the trajectory is unmistakable: the goal is not merely to slow aging but to reverse it at the cellular level.

NAD+ boosters and metabolic interventions target the molecular machinery of energy production that declines with age. Nicotinamide adenine dinucleotide (NAD+), a coenzyme essential to cellular metabolism, drops by roughly 50% between the ages of 40 and 60. Companies like Elysium Health and ChromaDex have brought NAD+ precursors to market, while clinical trials explore whether restoring NAD+ levels can improve cardiovascular function, cognitive performance, and metabolic health.

AI-powered drug discovery is compressing timelines that once spanned decades. Insilico Medicine used its AI platform to identify a novel target for idiopathic pulmonary fibrosis and advance a candidate into Phase 2 trials in under 30 months — a process that traditionally takes six to ten years. Isomorphic Labs, a DeepMind spinout, is applying AlphaFold’s protein structure predictions to aging-related targets. When artificial intelligence can screen billions of molecular combinations and predict biological outcomes in silico, the pace of longevity research accelerates exponentially.

Organ regeneration and bioprinting are extending the frontier further still. Researchers at the Karolinska Institute have demonstrated that transplanted lab-grown tissues can integrate with host biology. Japanese institutions, building on Shinya Yamanaka’s Nobel Prize-winning work on induced pluripotent stem cells (iPSCs), are pioneering clinical applications in retinal regeneration, cardiac tissue repair, and Parkinson’s disease. The vision — replacement organs grown from a patient’s own cells — is no longer theoretical.

Japan: The World’s Laboratory for Longevity

Japan does not merely study longevity. It lives it.

With a life expectancy of 84.6 years — the highest among major economies — and more than 95,000 centenarians, Japan is the world’s most advanced case study in what happens when a society ages profoundly. The proportion of citizens over 65 surpassed 29% in 2025 and is projected to reach 35% by 2040. No other large economy has navigated this territory.

This demographic reality has produced a research ecosystem of unusual depth. RIKEN’s Center for Biosystems Dynamics Research is at the forefront of organoid technology and regenerative medicine. The University of Tokyo’s Institute for the Biology of Aging is investigating the molecular mechanisms that allow certain populations — Okinawans among them — to maintain cognitive and physical function into their tenth decade. Keio University’s Center for Supercentenarian Research has built one of the world’s most comprehensive datasets on individuals who live past 110, generating insights into the genetic and environmental factors that differentiate extreme longevity from mere survival.

Japan’s regulatory environment, often caricatured as conservative, has in fact been remarkably forward-leaning in regenerative medicine. The 2014 Act on the Safety of Regenerative Medicine created a fast-track approval pathway that allows promising cell therapies to reach patients years before they would in the United States or Europe. The Pharmaceuticals and Medical Devices Agency (PMDA) has become a model for regulators seeking to balance innovation speed with patient safety.

The economic imperative is equally acute. Japan’s healthcare expenditure surpassed JPY 46 trillion ($310 billion) in 2025, with age-related conditions driving the majority of cost growth. The national pension system faces structural pressures as the ratio of working-age contributors to retirees continues to narrow. Every year of healthy life expectancy added — healthspan, not merely lifespan — translates into reduced medical costs, extended workforce participation, and a more sustainable social contract. For Japan, longevity technology is not a luxury. It is fiscal survival.

The Longevity Economy: A $44 Trillion Opportunity

The numbers are staggering. AARP and Oxford Economics estimate that individuals over 50 already contribute $44 trillion annually to the global economy — a figure projected to grow as populations age across every major market. The global longevity and anti-aging market, valued at approximately $65 billion in 2025, is expected to exceed $120 billion by 2030, with compounding growth driven by the convergence of biotech, digital health, and consumer wellness.

For investors and corporate strategists, the opportunity segments across multiple horizons.

Near-term (2026-2030): Wearable health monitoring, AI-powered diagnostics, personalized nutrition, digital therapeutics, and telehealth platforms. Companies like Oura, Whoop, and Japanese players such as Omron Healthcare are already capturing consumer demand for continuous health optimization. The market for AI in healthcare alone is projected to reach $45 billion by 2030.

Medium-term (2028-2035): Senolytic therapies reaching commercial approval, gene therapies for age-related diseases, bioprinted tissues for transplantation, and comprehensive biomarker-based health assessments replacing annual physicals. BioAge Labs, backed by $300 million in funding, is targeting muscle and metabolic aging with therapies designed to extend healthy function.

Long-term (2035-2050): Whole-organ regeneration, AI systems capable of predicting and preventing disease years before symptoms appear, and interventions that target the fundamental mechanisms of aging itself. Calico, Alphabet’s longevity research company, operates with a time horizon and budget that few private-sector labs can match, pursuing basic research into the biology of lifespan with the patient capital that breakthrough science demands.

The Hard Questions: Ethics, Equity, and the Social Contract

A future in which humans routinely live to 100 or beyond raises questions that technology alone cannot answer.

Who gets access? If radical life extension therapies cost millions, the longevity divide could become the most consequential inequality of the century — a world in which the wealthy live decades longer than everyone else. The history of medical innovation suggests that costs eventually fall, but “eventually” is cold comfort to the generation that arrives too early.

What happens to work and retirement? If healthy lifespans extend to 100, the notion of retiring at 65 and spending 35 years in leisure is economically untenable and, for many, psychologically unsatisfying. Japan is already pioneering models: 40% of Japanese aged 65-69 continue working, the highest rate among G7 nations. But these are incremental adaptations. True longevity will require a wholesale reimagining of careers, education, and social purpose across a century-long life.

Can the planet sustain longer-lived populations? The environmental footprint of 10 billion people living to 100 is a question that demographers, climate scientists, and resource economists are only beginning to model. The counterargument — that healthier, more educated, longer-lived populations tend to have lower birth rates and higher productivity — is plausible but unproven at the scale the longevity revolution implies.

Who decides the pace? Regulatory frameworks designed for traditional drug development are poorly suited to interventions that target aging itself, which the FDA does not currently classify as a disease. The TAME trial (Targeting Aging with Metformin), the first FDA-approved clinical trial to test a drug specifically for aging, may change that classification — but the legal and ethical infrastructure for longevity medicine remains nascent.

These are not abstract philosophical exercises. They are strategic questions for every executive whose business model depends on assumptions about how long customers live, how long employees work, and how societies allocate resources across generations.

The Intersection: Technology, Capital, and Will

The longevity revolution sits at the precise intersection of forces that the Tech for Impact Summit was designed to address: transformative technology, massive capital flows, urgent societal need, and unanswered governance questions.

AI is accelerating drug discovery. Blockchain is enabling new models for health data ownership and clinical trial coordination. Japan’s demographic reality provides both the urgency and the living laboratory. The capital is flowing — over $5.2 billion was invested in longevity-focused startups in 2025 alone, a fourfold increase from 2020.

What remains is the harder work: aligning incentives across governments, corporations, researchers, and patients so that the gains from longevity technology are distributed broadly rather than concentrated among those who can already afford to live well.

Join the Conversation

On April 26, 2026, the Tech for Impact Summit will convene senior executives, policymakers, and technologists at Tokyo Garden Terrace Kioi Conference to confront the questions that define our collective trajectory toward 2050. The summit’s theme — “Beyond Boundaries: Building 2050 Together” — encompasses the longevity revolution as one of the most consequential boundaries humanity is preparing to cross.

Among the confirmed speakers: Yoshito Hori (GLOBIS), Kathy Matsui (MPower Partners), Taro Kono (former Minister of Digital Affairs), Charles Hoskinson (Cardano), Ken Suzuki (SmartNews), Jesper Koll (Monex Group), and Hiroshi Aoi (Marui Group) — leaders whose work spans the intersection of technology, capital, and social impact.

Whether you lead a healthcare enterprise, a biotech fund, or a technology company whose products will shape how the next generation ages, the longevity revolution demands your attention — and your participation.

Explore partnership and membership opportunities →

Watch highlights from previous summits: youtu.be/ujy7ZXflrt4

---

The Tech for Impact Summit is an invitation-only executive gathering taking place April 26, 2026, in Tokyo as a partner event of SusHi Tech Tokyo. Learn more at tech4impactsummit.com.